New Surgical Devices from Covidien
International health care products major Covidien (COV) recently launched three novel surgical devices geared to offer significant benefits to physicians and better patient outcomes.
The devices (the Versaport bladeless optical 5 millimeter/mm trocar and two line extensions to the company’s LigaSure sealer/divider portfolio), were displayed by the Ireland-based company at the recently held annual meet of the Society of American Gastrointestinal and Endoscopic Surgeons (“SAGES 2012”).
The new Versaport trocar has been designed to provide surgeons with clear visualization of the tissue layers during insertion in laparoscopic and thoracic surgeries. Its low-profile design delivers optimal maneuverability, even when the device is used in small spaces. The device is the latest addition to Covidien’s Versaport bladeless family of trocars.
Besides launching Versaport, Covidien has also extended its vessel sealing devices range by unveiling a couple of new shaft lengths (of 20 centimeter/cm and 44 cm) in its LigaSure 5 mm blunt tip sealer/divider portfolio. These new offerings will offer physicians greater versatility while performing procedures on patients with different body shapes and sizes.
Covidien is a leading global health care products company with a rich history of developing high-quality products in a cost-effective manner. It competes with Johnson & Johnson (JNJ), Becton Dickinson (BDX) and C.R. Bard (BCR), among others.
Covidien remains committed to rolling out new products and technologies, focusing on emerging markets, and boosting market share in core segments through investments in sales and marketing infrastructure. It has launched 100 new products over the last five years and is on track to introduce another 50 products over the next two years.
However, sustained pricing/procedure volume pressure represents a headwind. We are currently Neutral on the stock, supported by a short-term Zacks #3 Rank (Hold).
Read the Full Research Report on BCR
Read the Full Research Report on COV
Read the Full Research Report on BDX
Read the Full Research Report on JNJ
More From Zacks.com
